Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles

Neuron

Volumn 40, Issue 3, 2003, Pages 471-483

  Cruz, Jonathan C ^a   Tseng, Huang Chun ^a   Goldman, Joseph A ^a   Shih, Heather ^a   Tsai, Li Huei ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CYCLIN DEPENDENT KINASE 5; EPITOPE; PROTEIN P25; TAU PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; BRAIN ATROPHY; BRAIN CORTEX; BRAIN DEVELOPMENT; CELL LOSS; CONTROLLED STUDY; ENZYME ACTIVATION; FOREBRAIN; GENE OVEREXPRESSION; HIPPOCAMPUS; MOUSE; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NONHUMAN; PATHOLOGY; PERINATAL PERIOD; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 0345405447     PISSN: 08966273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0896-6273(03)00627-5     Document Type: Article

References (59)

1. Ahlijanian M.K., Barrezueta N.X., Williams R.D., Jakowski A., Kowsz K.P., McCarthy S., Coskran T., Carlo A., Seymour P.A., Burkhardt J.E., et al. Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc. Natl. Acad. Sci. USA. 97:2000;2910-2915.
2. Ahuja H.S., Zhu Y., Zakeri Z. Association of cyclin-dependent kinase 5 and its activator p35 with apoptotic cell death. Dev. Genet. 21:1997;258-267.
3. Allen B., Ingram E., Takao M., Smith M.J., Jakes R., Virdee K., Yoshida H., Holzer M., Craxton M., Emson P.C., et al. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J. Neurosci. 22:2002;9340-9351.
4. Alvarez A., Munoz J.P., Maccioni R.B. A Cdk5-p35 stable complex is involved in the beta-amyloid-induced deregulation of Cdk5 activity in hippocampal neurons. Exp. Cell Res. 264:2001;266-274.
5. Angelo M., Plattner F., Irvine E.E., Giese K.P. Improved reversal learning and altered fear conditioning in transgenic mice with regionally restricted p25 expression. Eur. J. Neurosci. 18:2003;423-431.
6. Augustinack J.C., Sanders J.L., Tsai L.H., Hyman B.T. Colocalization and fluorescence resonance energy transfer between cdk5 and AT8 suggests a close association in pre-neurofibrillary tangles and neurofibrillary tangles. J. Neuropathol. Exp. Neurol. 61:2002;557-564.
7. Baumann K., Mandelkow E.M., Biernat J., Piwnica-Worms H., Mandelkow E. Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin- dependent kinases cdk2 and cdk5. FEBS Lett. 336:1993;417-424.
8. Bian F., Nath R., Sobocinski G., Booher R.N., Lipinski W.J., Callahan M.J., Pack A., Wang K.K., Walker L.C. Axonopathy, tau abnormalities, and dyskinesia, but no neurofibrillary tangles in p25-transgenic mice. J. Comp. Neurol. 446:2002;257-266.
9. Bird T.D., Nochlin D., Poorkaj P., Cherrier M., Kaye J., Payami H., Peskind E., Lampe T.H., Nemens E., Boyer P.J., et al. A clinical pathological comparison of three families with frontotemporal dementia and identical mutations in the tau gene (P301L). Brain. 122:1999;741-756.
10. Bu B., Li J., Davies P., Vincent I. Deregulation of cdk5, hyperphosphorylation, and cytoskeletal pathology in the Niemann-Pick type C murine model. J. Neurosci. 22:2002;6515-6525.
11. Delalle I., Bhide P.G., Caviness V.S. Jr., Tsai L.H. Temporal and spatial patterns of expression of p35, a regulatory subunit of cyclin-dependent kinase 5, in the nervous system of the mouse. J. Neurocytol. 26:1997;283-296.
12. Dhavan R., Tsai L.H. A decade of CDK5. Nat. Rev. Mol. Cell Biol. 2:2001;749-759.
13. Grace E.A., Busciglio J. Aberrant activation of focal adhesion proteins mediates fibrillar amyloid beta-induced neuronal dystrophy. J. Neurosci. 23:2003;493-502.
14. Gupta A., Tsai L.H., Wynshaw-Boris A. Life is a journey. a genetic look at neocortical development Nat. Rev. Genet. 3:2002;342-355.
15. Hashiguchi M., Saito T., Hisanaga S., Hashiguchi T. Truncation of CDK5 activator p35 induces intensive phosphorylation of Ser202/Thr205 of human tau. J. Biol. Chem. 277:2002;44525-44530.
16. Hisanaga S., Uchiyama M., Hosoi T., Yamada K., Honma N., Ishiguro K., Uchida T., Dahl D., Ohsumi K., Kishimoto T. Porcine brain neurofilament-H tail domain kinase. its identification as cdk5/p26 complex and comparison with cdc2/cyclin B kinase Cell Motil. Cytoskeleton. 31:1995;283-297.
17. Iijima K., Ando K., Takeda S., Satoh Y., Seki T., Itohara S., Greengard P., Kirino Y., Nairn A.C., Suzuki T. Neuron-specific phosphorylation of Alzheimer's beta-amyloid precursor protein by cyclin-dependent kinase 5. J. Neurochem. 75:2000;1085-1091.
18. Jackson G.R., Wiedau-Pazos M., Sang T.K., Wagle N., Brown C.A., Massachi S., Geschwind D.H. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron. 34:2002;509-519.
19. Keshvara L., Magdaleno S., Benhayon D., Curran T. Cyclin-dependent kinase 5 phosphorylates disabled 1 independently of Reelin signaling. J. Neurosci. 22:2002;4869-4877.
20. Ko J., Humbert S., Bronson R.T., Takahashi S., Kulkarni A.B., Li E., Tsai L.H. p35 and p39 are essential for cyclin-dependent kinase 5 function during neurodevelopment. J. Neurosci. 21:2001;6758-6771.
21. Kusakawa G., Saito T., Onuki R., Ishiguro K., Kishimoto T., Hisanaga S. Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25. J. Biol. Chem. 275:2000;17166-17172.
22. Lee V.M., Balin B.J., Otvos L. Jr., Trojanowski J.Q. A68. a major subunit of paired helical filaments and derivatized forms of normal tau Science. 251:1991;675-678.
23. Lee K.Y., Clark A.W., Rosales J.L., Chapman K., Fung T., Johnston R.N. Elevated neuronal Cdc2-like kinase activity in the Alzheimer disease brain. Neurosci. Res. 34:1999;21-29.
24. Lee M.S., Kwon Y.T., Li M., Peng J., Friedlander R.M., Tsai L.H. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature. 405:2000;360-364.
25. Lew J., Huang Q.Q., Qi Z., Winkfein R.J., Aebersold R., Hunt T., Wang J.H. A brain-specific activator of cyclin-dependent kinase 5. Nature. 371:1994;423-426.
26. Lewis J., McGowan E., Rockwood J., Melrose H., Nacharaju P., Van Slegtenhorst M., Gwinn-Hardy K., Paul Murphy M., Baker M., Yu X., et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 25:2000;402-405.
27. Lewis J., Dickson D.W., Lin W.L., Chisholm L., Corral A., Jones G., Yen S.H., Sahara N., Skipper L., Yager D., et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 293:2001;1487-1491.
28. Li B.S., Zhang L., Takahashi S., Ma W., Jaffe H., Kulkarni A.B., Pant H.C. Cyclin-dependent kinase 5 prevents neuronal apoptosis by negative regulation of c-Jun N-terminal kinase 3. EMBO J. 21:2002;324-333.
29. Li G., Faibushevich A., Turunen B.J., Yoon S.O., Georg G., Michaelis M.L., Dobrowsky R.T. Stabilization of the cyclin-dependent kinase 5 activator, p35, by paclitaxel decreases beta-amyloid toxicity in cortical neurons. J. Neurochem. 84:2003;347-362.
30. Liou Y.C., Sun A., Ryo A., Zhou X.Z., Yu Z.X., Huang H.K., Uchida T., Bronson R., Bing G., Li X., et al. Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration. Nature. 424:2003;556-561.
31. Lucas J.J., Hernandez F., Gomez-Ramos P., Moran M.A., Hen R., Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 20:2001;27-39.
32. Mayford M., Bach M.E., Huang Y.Y., Wang L., Hawkins R.D., Kandel E.R. Control of memory formation through regulated expression of a CaMKII transgene. Science. 274:1996;1678-1683.
33. Nath R., Davis M., Probert A.W., Kupina N.C., Ren X., Schielke G.P., Wang K.K. Processing of cdk5 activator p35 to its truncated form (p25) by calpain in acutely injured neuronal cells. Biochem. Biophys. Res. Commun. 274:2000;16-21.
34. Nguyen M.D., Lariviere R.C., Julien J.P. Deregulation of Cdk5 in a mouse model of ALS. toxicity alleviated by perikaryal neurofilament inclusions Neuron. 30:2001;135-147.
35. Niethammer M., Smith D.S., Ayala R., Peng J., Ko J., Lee M.S., Morabito M., Tsai L.H. NUDEL is a novel Cdk5 substrate that associates with LIS1 and cytoplasmic dynein. Neuron. 28:2000;697-711.
36. Noble W., Olm V., Takata K., Casey E., Mary O., Meyerson J., Gaynor K., LaFrancois J., Wang L., Kondo T., et al. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron. 38:2003;555-565.
37. Otth C., Concha I.I., Arendt T., Stieler J., Schliebs R., Gonzalez-Billault C., Maccioni R.B. AbetaPP induces cdk5-dependent tau hyperphosphorylation in transgenic mice Tg2576. J. Alzheimers Dis. 4:2002;417-430.
38. Patrick G.N., Zukerberg L., Nikolic M., de la Monte S., Dikkes P., Tsai L.H. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature. 402:1999;615-622.
39. Paudel H.K., Lew J., Ali Z., Wang J.H. Brain proline-directed protein kinase phosphorylates tau on sites that are abnormally phosphorylated in tau associated with Alzheimer's paired helical filaments. J. Biol. Chem. 268:1993;23512-23518.
40. Pei J.J., Grundke-Iqbal I., Iqbal K., Bogdanovic N., Winblad B., Cowburn R.F. Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration. Brain Res. 797:1998;267-277.
41. Sasaki S., Shionoya A., Ishida M., Gambello M.J., Yingling J., Wynshaw-Boris A., Hirotsune S. A LIS1/NUDEL/cytoplasmic dynein heavy chain complex in the developing and adult nervous system. Neuron. 28:2000;681-696.
42. Sharma P., Veeranna, Sharma M., Amin N.D., Sihag R.K., Grant P., Ahn N., Kulkarni A.B., Pant H.C. Phosphorylation of MEK1 by cdk5/p35 down-regulates the mitogen-activated protein kinase pathway. J Biol. Chem. 277:2002;528-534.
43. Sun A., Nguyen X.V., Bing G. Comparative analysis of an improved thioflavin-s stain, Gallyas silver stain, and immunohistochemistry for neurofibrillary tangle demonstration on the same sections. J. Histochem. Cytochem. 50:2002;463-472.
44. Takashima A., Murayama M., Yasutake K., Takahashi H., Yokoyama M., Ishiguro K. Involvement of cyclin dependent kinase5 activator p25 on tau phosphorylation in mouse brain. Neurosci. Lett. 306:2001;37-40.
45. Tang D., Yeung J., Lee K.Y., Matsushita M., Matsui H., Tomizawa K., Hatase O., Wang J.H. An isoform of the neuronal cyclin-dependent kinase 5 (Cdk5) activator. J. Biol. Chem. 270:1995;26897-26903.
46. Taniguchi S., Fujita Y., Hayashi S., Kakita A., Takahashi H., Murayama S., Saido T.C., Hisanaga S., Iwatsubo T., Hasegawa M. Calpain-mediated degradation of p35 to p25 in postmortem human and rat brains. FEBS Lett. 489:2001;46-50.
47. Tomizawa K., Matsui H., Matsushita M., Lew J., Tokuda M., Itano T., Konishi R., Wang J.H., Hatase O. Localization and developmental changes in the neuron-specific cyclin-dependent kinase 5 activator (p35nck5a) in the rat brain. Neuroscience. 74:1996;519-529.
48. Town T., Zolton J., Shaffner R., Schnell B., Crescentini R., Wu Y., Zeng J., DelleDonne A., Obregon D., Tan J., et al. p35/Cdk5 pathway mediates soluble amyloid-beta peptide-induced tau phosphorylation in vitro. J. Neurosci. Res. 69:2002;362-372.
49. Tsai L.H., Delalle I., Caviness V.S. Jr., Chae T., Harlow E. p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature. 371:1994;419-423.
50. Tseng H.C., Zhou Y., Shen Y., Tsai L.H. A survey of Cdk5 activator p35 and p25 levels in Alzheimer's disease brains. FEBS Lett. 523:2002;58-62.
51. Van den Haute C., Spittaels K., Van Dorpe J., Lasrado R., Vandezande K., Laenen I., Geerts H., Van Leuven F. Coexpression of human cdk5 and its activator p35 with human protein tau in neurons in brain of triple transgenic mice. Neurobiol. Dis. 8:2001;32-44.
52. Williamson R., Scales T., Clark B.R., Gibb G., Reynolds C.H., Kellie S., Bird I.N., Varndell I.M., Sheppard P.W., Everall I., et al. Rapid tyrosine phosphorylation of neuronal proteins including tau and focal adhesion kinase in response to amyloid-beta peptide exposure. involvement of Src family protein kinases J. Neurosci. 22:2002;10-20.
53. Wittmann C.W., Wszolek M.F., Shulman J.M., Salvaterra P.M., Lewis J., Hutton M., Feany M.B. Tauopathy in Drosophila. neurodegeneration without neurofibrillary tangles Science. 293:2001;711-714.
54. Wolozin B.L., Pruchnicki A., Dickson D.W., Davies P. A neuronal antigen in the brains of Alzheimer patients. Science. 232:1986;648-650.
55. Yamamoto A., Lucas J.J., Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell. 101:2000;57-66.
56. Yang H.S., Hinds P.W. Increased ezrin expression and activation by CDK5 coincident with acquisition of the senescent phenotype. Mol. Cell. 11:2003;1163-1176.
57. Yoo B.C., Lubec G. p25 protein in neurodegeneration. Nature. 411:2001;763-764. discussion 764-765.
58. Zhang J., Krishnamurthy P.K., Johnson G.V. Cdk5 phosphorylates p53 and regulates its activity. J. Neurochem. 81:2002;307-313.
59. Zhu X., Lee H.G., Raina A.K., Perry G., Smith M.A. The role of mitogen-activated protein kinase pathways in Alzheimer's disease. Neurosignals. 11:2002;270-281.